BASF Se (BAS.SW)

Capital Expenditure

-€3.69B

TTM · Period ending: · EUR

BAS.SW logo

BAS.SW Capital Expenditure

Latest reported-€3.69B EUR
BAS.SW TTM CapEx · EUR (-€2.90B → -€3.69B)
High-resolution chart · PNG

BAS.SW capital expenditure history

Trailing twelve months (TTM) · EUR. Each value covers four complete reported quarters.

BASF Se Capital Expenditure — Trailing twelve months (TTM) (EUR)
Period endingCapital Expenditure (EUR)
-3,690,553,229
-4,030,553,229
-4,267,894,135
-5,134,000,000
-5,644,000,000
-6,071,000,000
-6,198,000,000
-5,941,000,000
-5,678,000,000
-5,471,000,000
-5,395,000,000
-5,235,000,000
-5,020,000,000
-4,639,000,000
-4,375,000,000
-3,991,000,000
-3,804,000,000
-3,679,000,000
-3,532,000,000
-3,140,000,000
-3,057,000,000
-3,016,000,000
-3,129,000,000
-3,207,000,000
-3,397,000,000
-3,652,000,000
-3,824,000,000
-4,114,000,000
-4,167,000,000
-4,008,000,000
-3,894,000,000
-3,818,000,000
-3,803,000,000
-3,856,000,000
-3,996,000,000
-3,836,000,000
-3,808,000,000
-3,911,000,000
-4,145,000,000
-4,340,000,000
-4,946,000,000
-5,535,000,000
-5,812,000,000
-6,257,000,000
-6,101,000,000
-5,759,000,000
-5,417,000,000
-5,169,000,000
-4,937,000,000
-4,765,000,000
-4,660,000,000
-4,407,000,000
-4,364,000,000
-4,260,000,000
-4,149,000,000
-4,089,000,000
-3,814,000,000
-3,583,000,000
-3,410,000,000
-3,131,000,000
-2,924,000,000
-2,703,000,000
-2,548,000,000
-2,197,000,000
-2,098,000,000
-2,329,000,000
-2,507,000,000
-2,706,000,000
-2,770,000,000
-2,628,000,000
-2,521,000,000
-2,533,400,000
-2,555,697,670
-2,560,544,240
-2,562,400,000
-2,504,614,477
-2,482,872,487
-2,383,223,147
-2,410,898,357
-2,241,148,034
-2,056,941,704
-2,046,094,614
-1,946,221,514
-1,858,272,722
-1,893,717,132
-1,892,414,292
-1,932,371,202
-1,974,515,783
-2,013,765,163
-2,050,911,323
-2,067,684,293
-2,321,935,660
-2,358,475,240
-2,389,279,980
-2,412,579,830
-2,267,838,874
-2,535,036,254
-2,713,981,404
-2,815,493,454
-2,970,057,194
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.